Compare · NTRA vs RDNT
NTRA vs RDNT
Side-by-side comparison of Natera Inc. (NTRA) and RadNet Inc. (RDNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and RDNT operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $57.03B, about 10.1x RDNT ($5.63B).
- Over the past year, NTRA is up 120.1% and RDNT is down 9.9% - NTRA leads by 130.0 points.
- NTRA has been more active in the news (10 items in the past 4 weeks vs 2 for RDNT).
- NTRA has more recent analyst coverage (25 ratings vs 10 for RDNT).
- Company
- Natera Inc.
- RadNet Inc.
- Price
- $394.98-0.19%
- $69.19-3.32%
- Market cap
- $57.03B
- $5.63B
- 1M return
- +12.56%
- -10.32%
- 1Y return
- +120.09%
- -9.87%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 10
- 2
- Recent ratings
- 25
- 10
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
RadNet Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
Latest NTRA
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $7,008,972 worth of shares (18,064 units at $388.01) as part of a pre-agreed trading plan (SEC Form 4)
- Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Latest RDNT
- New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies
- RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals
- RadNet to Host Free Prostate Cancer Webinar on September 19, 2026
- RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026
- RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
- RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by RadNet Inc.
- RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
- DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound